Quarterly ResultApr 30, 2026, 06:06 PM
INCR FY2025 Revenue >NIS 270M (+13%); Adj. EBITDA NIS 47M (+90%)
AI Summary
InterCure Ltd. reported strong FY2025 financial results, with revenue exceeding NIS 270 million, a 13% increase from 2024, and Adjusted EBITDA of NIS 47 million, up over 90% year-over-year, marking its twelfth consecutive half-year of positive Adjusted EBITDA. The company also achieved positive operating cash flow of NIS 17 million. Strategically, InterCure resumed production at its Nir Oz facility, launched over 75 new GMP SKUs, expanded into the German market, and made key investments including the acquisition of Botanico Ltd. and a strategic stake in Cannasoul R&D Ltd., positioning for continued global expansion and pharmaceutical capabilities.
Key Highlights
- Acquired Botanico Ltd. to strengthen genetics and cultivation, anticipating >NIS 30M revenue in H2 2026.
- Invested in Cannasoul R&D Ltd., acquiring 28% ownership with an exclusive path to 51%.
- FY2025 revenue exceeded NIS 270 million, a 13% increase from 2024.
- Adjusted EBITDA reached NIS 47 million, up over 90% from NIS 24 million in 2024.
- Reported a net loss of NIS 37 million, an improvement from NIS 73 million in 2024.
- Generated NIS 17 million in positive operating cash flow, compared to negative NIS 67 million in 2024.
- Resumed production and sales from Nir Oz facility, delivering first batches since Oct 7, 2023.
- Launched over 75 new GMP SKUs and saw significant revenue contributions from the German market.